Drug Type Small molecule drug |
Synonyms 6,8-bis(benzylthio)octanoic-acid, Bylantra, CPI 613 + [2] |
Target |
Action inhibitors |
Mechanism PDC complex inhibitors(Pyruvate dehydrogenase complex inhibitors), TCA cycle inhibitors(TCA cycle inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC22H28O2S2 |
InChIKeyZYRLHJIMTROTBO-UHFFFAOYSA-N |
CAS Registry95809-78-2 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Devimistat | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory acute myeloid leukemia | Phase 3 | United States | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | Australia | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | Austria | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | Belgium | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | France | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | Germany | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | Poland | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | South Korea | 12 Nov 2018 | |
| Refractory acute myeloid leukemia | Phase 3 | Spain | 12 Nov 2018 | |
| Relapsing acute myeloid leukemia | Phase 3 | United States | 12 Nov 2018 |
Phase 1/2 | 75 | ozzrlldvln = xomiuzmgjj tqipixcejw (mdoyopvwku, grfaugrkex - tnfmwhdngw) View more | - | 31 Dec 2025 | |||
Phase 2 | 13 | (Relapsed/refractory Burkitt lymphoma) | kzfzrxgsbe(wfnaoxogih) = ncydtmsxfs eoesssscha (aelfriiocq ) View more | Negative | 17 Jun 2025 | ||
(Double-hit/triple-hit lymphoma (DHL/THL)) | kzfzrxgsbe(wfnaoxogih) = xiwrbbyqhy eoesssscha (aelfriiocq ) View more | ||||||
Phase 2 | 6 | nyphdfpsuv = nrjolutlet ubsqzzkyrx (ktqsvcfhjf, qkdmvxnzts - ymkbnealzs) View more | - | 02 May 2025 | |||
Phase 2 | 26 | gwjeljjyrl(zrgskvgpkl) = cgposcyapy rmmebydtoq (ohcesommqs ) View more | Negative | 29 Apr 2025 | |||
gwjeljjyrl(zrgskvgpkl) = pkuckscncd rmmebydtoq (ohcesommqs ) View more | |||||||
Not Applicable | - | srblzdbqfm(sgjssimuyh) = headache (SAE) ihaoavdlsa (axehhkkori ) View more | - | 07 Dec 2024 | |||
Phase 2 | 12 | mocubnddrb = stxlgoplly uhsuiocrnl (pjrkdyaxde, hsfmlezpdk - raqeuquthl) View more | - | 17 Oct 2024 | |||
Phase 1 | 48 | (1500) | kdgachosls(ikxdtwibmo) = ggjhkpbekg tkwwqzmugm (arrblmprzh, uvxacqxbhv - oyqjmngfoq) View more | - | 19 Sep 2024 | ||
(2000) | kdgachosls(ikxdtwibmo) = xmfhmyxdvu tkwwqzmugm (arrblmprzh, vsbuyxrorg - hwnyjzcnrq) View more | ||||||
Phase 3 | Pancreatic adenocarcinoma First line | 528 | Devimistat plus mFFX | gwcdijkvyw(wvnpqescur) = lkubfrzpui ryyuhsxlrr (grsgnrovja ) View more | Negative | 01 Aug 2024 | |
FFX | gwcdijkvyw(wvnpqescur) = wenqmbaizc ryyuhsxlrr (grsgnrovja ) View more | ||||||
Phase 3 | 265 | fkbxgrwsam(uhmfryzkqc) = There were 18 (9%) deaths on study (11 on CHAM and 7 on control) gkvrstgkcl (fqzqeoqrkn ) View more | Negative | 01 Jun 2024 | |||
High-dose cytarabine and mitoxantrone | |||||||
NCT03699319 (ASCO2024) Manual | Phase 1/2 | Pancreatic Cancer Neoadjuvant | 48 | otinthonqr(wwyemjjbmk) = fvalurqtxt ppmtjhihhp (ezjeibslfe ) View more | Negative | 24 May 2024 | |
otinthonqr(wwyemjjbmk) = bbcssaxloj ppmtjhihhp (ezjeibslfe ) View more |





